The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Published version of a preprint
Abstract
mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of mRNA-4157 via characterization of T-cell responses to neoantigens from the first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non–small cell lung cancer (Part A: 1-mg mRNA-4157, n = 4) or resected cutaneous melanoma (Part D: 1-mg mRNA-4157 + 200-mg pembrolizumab, n = 12). Safety, tolerability, and immunogenicity were assessed. All patients experienced ≥1 treatment-emergent adverse event; there were no grade 4/5 adverse events or dose-limiting toxicities. mRNA-4157 alone induced consistent de novo and strengthened preexisting T-cell responses to targeted neoantigens. Following combination therapy, sustained mRNA-4157-induced neoantigen-specific T-cell responses and expansion of cytotoxic CD8 and CD4 T cells were observed. These findings show the potential of a novel mRNA individualized neoantigen therapy approach in oncology. Significance: The safety and immunogenicity results from this phase 1 study of mRNA-4157 as adjuvant monotherapy or combination therapy with pembrolizumab show generation of de novo and enhancement of existing neoantigen-specific T-cell responses and provide mechanistic proof of concept to support further development of mRNA-4157 for patients with resected solid tumors. See related commentary by Berraondo et al., p. 2021
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [19]
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Weber, J. S., Carlino, M. S., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M. H., Kim, K. B., McKean, M., Long, G. V., Sullivan, R. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02268-7 · Cited by 916
Self-citationExploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 802
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
Self-citationXu, C., Chen, Y., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G., Li, W., Mao, Y., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 566
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 431
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J. K., Chang, A. E., & Zou, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6730 · Cited by 425
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Impact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354
Self-citationThe Immune Revolution: A Case for Priming, Not Checkpoint
Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 301
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K., Xin, C.-F., Hong, M. H., Ahn, B., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 286
The prevalence of Th17 cells in patients with gastric cancer
Zhang, B., Rong, G., Wei, H., Zhang, M., Bi, J., Ma, L., Xue, X., Wei, G., Liu, X., & Fang, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.060 · Cited by 262
Lee, A., Sun, L., Mochizuki, A. Y., Reynoso, J. G., Orpilla, J. R., Chow, F. E., Kienzler, J. C., Everson, R. G., Nathanson, D. A., Bensinger, S. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26940-2 · Cited by 262
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
Patel, R. S., Kaki, M., Potluri, V., Kahar, P., & Khanna, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002083 · Cited by 252
T-cell repertoire analysis and metrics of diversity and clonality
Chiffelle, J., Genolet, R., Perez, M. A. S., Coukos, G., Zoete, V., & Harari, A. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.07.010 · Cited by 212
Lee, H. L., Jang, J. W., Lee, S. W., Yoo, S. H., Kwon, J. H., Nam, S. W., Bae, S. H., Choi, J. Y., Han, N. I., & Yoon, S. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-40078-8 · Cited by 190
Burris, H. A., Patel, M. R., Cho, D. C., Clarke, J. M., Gutierrez, M., Zaks, T. Z., Frederick, J., Hopson, K., Mody, K., Binanti-Berube, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2523 · Cited by 144
Self-citationArrieta‐Bolaños, E., Hernández-Zaragoza, D. I., & Barquera, R. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.866407 · Cited by 140
mRNA vaccine trafficking and resulting protein expression after intramuscular administration
Hassett, K. J., Rajlic, I. L., Bahl, K., White, R. A., Cowens, K. B., Jacquinet, E., & Burke, K. E. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102083 · Cited by 128
Cai, Z., Su, X., Qiu, L., Li, Z., Li, X., Dong, X., Wei, F., Zhou, Y., Luo, L., Chen, G., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01467-8 · Cited by 123
Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 122
Melero, I., Singhal, M. C., McGowan, P., Haugen, H. S., Blake, J., Hellström, K. E., Yang, G., Clegg, C. H., & Chen, L. (1997) · Journal of Virology · doi:10.1128/jvi.71.5.3998-4004.1997 · Cited by 85
Linette, G. P., Becker‐Hapak, M., Skidmore, Z. L., Baroja, M. L., Xu, C. B., Hundal, J., Spencer, D. H., Fu, W., Cummins, C., Robnett, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906026116 · Cited by 64
Achieving high-sensitivity for clinical applications using augmented exome sequencing
Patwardhan, A. J., Harris, J., Leng, N., Bartha, G. T., Church, D. M., Luo, S. J., Haudenschild, C. D., Pratt, M., Zook, J. M., Salit, M., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0197-4 · Cited by 57
Wei, L., Zhang, H., Niu, Z., Wang, Z., Kong, Y., Yang, X., & Yuan, F. (2020) · BMC Women s Health · doi:10.1186/s12905-020-00972-0 · Cited by 52
Tumor Regression and Cure Depends on Sustained Th1 Responses
Dai, M., Hellström, I., Yip, Y. Y., Sjögren, H. O., & Hellström, K. E. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000231 · Cited by 38
Montagne, J. M., Zheng, X. A., Pinal‐Fernandez, I., Milisenda, J. C., Christopher‐Stine, L., Lloyd, T. E., Mammen, A. L., & Larman, H. B. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102972 · Cited by 20
Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 15
Koelblinger, P., Hoellwerth, M., Dernoscheg, M., Koch, L., Richtig, E., Wanner, M., Nguyen, V., Ostermann, H., Bauer, J. W., & Laimer, M. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14511 · Cited by 15
Zhong, S., Breton, B., Zheng, W., McFadyen, I. J., Hopson, K., Frederick, J. P., Meehan, R. S., & Zaks, T. Z. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-6539 · Cited by 10
Self-citationAnalytical validation of comprehensive assays for genomic profiling of cancer from DNA and RNA
Beck, J., Newburn, E. N., Clark, M., Lefterova, M. I., Helman, E., Alla, R., Church, D. M., Boyle, S., Luo, S., Morra, M., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32781-2 · Cited by 1
Yen, J. L., Boyle, S., Alla, R., Harris, J., Lefterova, M. I., & Chen, R. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-546 · Cited by 1
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105
Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C., Leal, A. D., Chung, V. M., Perry, J., Kheoh, T. S., McNeil, L. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03876-4 · Cited by 101
The next generation of immunotherapies for lung cancers
Zhao, S., Zhao, H., Yang, W., & Zhang, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01035-9 · Cited by 96
Sun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 101
Metadata
- Authors
- Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., Robert-Tissot, C., Coder, B., Tasneem, M., Sun, J., Zheng, W., Gerbereux, L., Laino, A., Porichis, F., Pollard, J. R., Hou, P., Sehgal, V., Chen, X., Morrissey, M., Daghestani, H. N., Feldman, I., Srinivasan, L., Frederick, J. P., Brown, M., Aanur, P., Meehan, R., & Burris, H. A.
- Affiliations
- Massachusetts General Hospital (US)
- Sarah Cannon (US)
- NYU Langone Health (US)
- Hackensack University Medical Center (US)
- George Washington University (US)
- Duke University (US)
- University of Arizona Cancer Center (US)
- Banner - University Medical Center Tucson (US)
- Cleveland Clinic (US)
- Moffitt Cancer Center (US)
- 11Moderna, Inc., Cambridge, Massachusetts.
- Moderna Therapeutics (United States) (US)
- HiFiBiO Therapeutics (United States) (US)
- ORCID
- Gainor, Justin F.
- Patel, Manish R.
- Weber, Jeffrey S.
- Gutierrez, Martin
- Bauman, Julie E.
- Clarke, Jeffrey M.
- Julian, Ricklie
- Scott, Aaron J.
- Geiger, Jessica L.
- Kirtane, Kedar
- Robert-Tissot, Celine
- Coder, Brandon
- Tasneem, Moomal
- Sun, Jing
- Zheng, Wei
- Gerbereux, Lauren
- Laino, Andressa
- Porichis, Filippos
- Pollard, Jack Russella
- Hou, Peijie
- Sehgal, Vasudha
- Chen, Xing
- Morrissey, Manju
- Daghestani, Hikmat N.
- Feldman, Igor
- Srinivasan, Lakshmi
- Frederick, Joshua P.
- Brown, Michelle
- Aanur, Praveen
- Meehan, Robert
- Burris, Howard A.
- Venue
- Cancer Discovery
- Published
- 2024-08-08
- Volume
- 14
- Issue
- 11
- Pages
- 2209-2223
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4401422221
- Cited by
- 124
- References
- 45
- Citations by year
- 2026: 58 · 2025: 63 · 2024: 3
- FWCI
- 20.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- neoantigens, T cell response, pembrolizumab, non-small cell lung cancer, cutaneous melanoma, mRNA vaccines, immunogenicity, CD8+ T cells, CD4+ T cells, adjuvant therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Melanoma, Middle Aged, Skin Neoplasms, T-Lymphocytes, Precision Medicine, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
